Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN).

Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet 2002;359:1453–60. A trial was completed comparing the different interferon therapies for multiple sclerosis. The results indicate that interferon β-1b therapy every other day is more effective than weekly interferon β-1a. More patients who received interferon β-1b remained relapse free, and remained free from new T2 lesions on MRI. The differences between the two treatment groups were more significant during the second year.